{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-154021","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2022-05-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.052758+00:00","generated_at":"2026-06-25T10:48:14.653735+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Vertex shareholders elect 11 directors, approve stock plan amendment adding 13.5M shares","bullets":["All 11 director nominees elected, with Reshma Kewalramani receiving 218.7M votes for.","Ratification of Ernst & Young as auditor for FY2022 passed with 177.8M for, 51.9M against.","Advisory say-on-pay approved, 202.2M for vs 16.1M against.","Amendment to 2013 Stock and Option Plan adding 13.5M shares authorized for issuance approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-154021","json":"https://secwatch.observer/filing/0001193125-22-154021.json","markdown":"https://secwatch.observer/filing/0001193125-22-154021.md","text":"https://secwatch.observer/filing/0001193125-22-154021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000119312522154021/0001193125-22-154021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000119312522154021/d272923d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T10:48:14.653735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}